First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Shares Shorted: Short Interest Down 50.2% in September

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) was the recipient of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totaling 9,470 shares, a decrease of 50.2% from the September 15th total of 19,031 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 468,724 shares, the short-interest ratio is currently 0.0 days.

First Trust Nasdaq Pharmaceuticals ETF Stock Down 0.7%

FTXH stock traded down $0.31 during trading on Friday, hitting $41.66. The company had a trading volume of 24,785 shares, compared to its average volume of 231,592. The firm has a market capitalization of $1.08 billion, a P/E ratio of 14.51 and a beta of 0.45. First Trust Nasdaq Pharmaceuticals ETF has a 52-week low of $28.85 and a 52-week high of $43.52. The company has a 50 day simple moving average of $41.17 and a 200-day simple moving average of $37.81.

First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Thursday, September 24th were given a dividend of $0.0113 per share. This represents a $0.05 dividend on an annualized basis and a dividend yield of 0.1%. This is a drop from First Trust Nasdaq Pharmaceuticals ETF’s previous quarterly dividend of $0.0920. The ex-dividend date of this dividend was Thursday, September 24th.

Institutional Trading of First Trust Nasdaq Pharmaceuticals ETF

Several institutional investors and hedge funds have recently modified their holdings of the stock. Trust Co. of Oklahoma bought a new position in First Trust Nasdaq Pharmaceuticals ETF in the third quarter worth approximately $1,283,000. MinichMacGregor Wealth Management LLC purchased a new position in First Trust Nasdaq Pharmaceuticals ETF during the 3rd quarter worth $968,000. Nilsine Partners LLC increased its holdings in First Trust Nasdaq Pharmaceuticals ETF by 3.5% during the 2nd quarter. Nilsine Partners LLC now owns 28,057 shares of the company’s stock worth $1,071,000 after purchasing an additional 937 shares during the period. Cyndeo Wealth Partners LLC purchased a new position in First Trust Nasdaq Pharmaceuticals ETF during the 3rd quarter worth $1,524,000. Finally, Compass Financial Management LLC purchased a new position in First Trust Nasdaq Pharmaceuticals ETF during the 2nd quarter worth $29,000.

About First Trust Nasdaq Pharmaceuticals ETF

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.